1-propionyl-2-oxo-imidazolidine | 55150-33-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: 1-propionyl-2-oxo-imidazolidine
• 英文别名: 1-propionylimidazolidin-2-one；1-propionyl-2-imidazolidone；1-propionyl-imidazolidin-2-one；1-Propionyl-imidazolidin-2-on；1-Propionyl-imidazolidinone-2；1-Propanoylimidazolidin-2-one
• CAS: 55150-33-9
• 化学式: C₆H₁₀N₂O₂
• mdl: MFCD19216967
• 分子量: 142.158
• InChiKey: MPSSSVUOOMDBRF-UHFFFAOYSA-N

物化性质

• 熔点：
  147.5-149.2 °C
• 密度：
  1.184±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  49.4
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  溴乙烯 、 1-propionyl-2-oxo-imidazolidine 在 copper(l) iodide 、 potassium carbonate 、 N,N'-二甲基乙二胺 作用下， 以 四氢呋喃 为溶剂， 反应 7.0h， 以83.6%的产率得到1-propionyl-3-vinyl-2-imidazolidone
  参考文献：
  名称：

  Ｎ−ビニルイミダゾリドン化合物、およびその重合体

  摘要：

  提供N-乙烯基咪唑烷酮化合物的聚合物，可望应用于细胞培养材料、温度响应材料等。N-乙烯基咪唑烷酮化合物（1）作为单体聚合得到的聚合物，或者由该单体和结构不同的单体共聚而成。（R1为H、C1-12的烷基或酰基；R2和R3为H或甲基）【选择图】无

  公开号：

  JP2016145198A
• 作为产物：
  描述：

  2-咪唑烷酮 、 1-(1H-benzo[d][1,2,3]triazol-1-yl)propan-1-one 在 potassium carbonate 作用下， 以 甲苯 为溶剂， 反应 2.5h， 以71%的产率得到1-propionyl-2-oxo-imidazolidine
  参考文献：
  名称：

  A Novel and Efficient Reaction of Imidazolidin-2-one andN-Acylbenzotriazoles: A Facile Synthesis of 1-Acylimidazolidin-2-one

  摘要：

  Acylation of imidazolidin-2-one with readily available N-acylbenzotriazoles, in the presence of K2CO3, produced 1-acylimidazolidin-2-ones and N,N'-diacyl-imidazolidin-2-one in moderate to good yields. The utilization of N-acylbenzotriazoles which make the reaction simple and mild, may be especially advantageous when the corresponding acid chlorides are not stable or not easily prepared. It's also an example of the reaction of N-acylbenzotriazoles and amide.

  DOI：

  10.1080/00397910903531615

文献信息

• Double Molecular Recognition with Aminoorganoboron Complexes: Selective Alcoholysis of β-Dicarbonyl Derivatives
  作者：Shunsuke Oishi、Susumu Saito

  DOI：10.1002/anie.201200304

  日期：2012.5.29

  Double duty: Aminoorganoboron (AOB) complexes recognize alcohol and β‐dicarbonyl units, and thereby facilitate chemo‐ and site‐selective alcoholysis of the latter (see scheme). The complex activates both reaction partners. This strategy enables CC, CN, and CO bond cleavage in addition/elimination reactions under near neutral pH conditions and provides a new method for functional group conversions

  双重职责：氨基有机硼酸盐（AOB）络合物识别醇和β-二羰基单元，从而促进后者的化学和位点选择性醇解（请参阅方案）。该复合物激活了两个反应伙伴。此策略可在接近中性pH的条件下在加成/消除反应中裂解CC，CN和CO键，并为官能团转化提供了一种新方法。
• Process for the manufacture of 2-arylamino-2-imidazoline derivatives and
  申请人：Boehringer Ingelheim GmbH

  公开号：US03931216A1

  公开（公告）日：1976-01-06

  A process for the preparation of the known and valuable 2-aryl-amino-2-imidazoline derivatives which comprises condensing an appropriately substituted aniline with a 1-acyl-imidazolidin-2-one to produce an intermediate compound which on neutralisation in an aqueous medium is converted into a N-acyl derivative of the 2-aryl-amino-2-imidazoline, and splitting the intermediate compound or the said N-acyl derivative to give the corresponding free arylamino-2-imidazoline derivative or a salt thereof.

  一种制备已知和有价值的2-芳基氨基-2-咪唑啉衍生物的方法，包括将适当取代的苯胺与1-酰基咪唑啉-2-酮缩合，产生一个中间化合物，在水性介质中中和后转化为2-芳基氨基-2-咪唑啉的N-酰基衍生物，然后分解中间化合物或所述的N-酰基衍生物，得到相应的游离芳基氨基-2-咪唑啉衍生物或其盐。
• ACETYL MIMIC COMPOUNDS FOR THE INHIBITION OF ISOPRENYL-S-CYSTEINYL METHYLTRANSFERASE
  申请人：Lee Seung-Yub

  公开号：US20110053901A1

  公开（公告）日：2011-03-03

  Among other things, the present invention provides novel compounds capable of effectively inhibiting inflammatory responses that are mediated by G-proteins or GPCRs in neutrophils, macrophages and platelets. In particular, compounds of the present invention act as inhibitors of edema, inhibitors of erythema and inhibitors of MPO (myeloperoxidase), pharmaceutical compositions containing the same compounds and the use thereof for the treatment of diseases that may benefit from edema, erythema and MPO inhibition, such as inflammation (acute or chronic), asthma, autoimmune diseases, and chronic obstructive pulmonary disease (COPD) (e.g., emphysema, chronic bronchitis and small airways disease, etc.), inflammatory responses of the immune system, skin diseases (e.g., reducing acute skin irritation for patients suffering from rosacea, atopic dermatitis, seborrheic dermatitis, psoriasis), irritable bowel syndrome (e.g., Chron's disease and ulcerative colitis, etc.), and central nervous system disorders (e.g., Parkinson's disease).
• US3931216A
  申请人：——

  公开号：US3931216A

  公开（公告）日：1976-01-06
• US3974141A
  申请人：——

  公开号：US3974141A

  公开（公告）日：1976-08-10